Phage Based Diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Menu
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us

New CEO appointed to drive expansion

Novel diagnostic developer PBD Biotech announces the appointment of new CEO Mark Hammond to drive the company’s expansion.
  • April 21, 2019
  • Company, People
Mark Hammond, PBD Biotech CEO

The success of the company’s Actiphage® test for rapid detection of TB and other mycobacterial disease is attracting international interest as it offers, for the first time, a means of managing these infections across multiple market sectors, from animal to human health and food quality control.

Bovine TB and Johne’s are devastating mycobacterial diseases that have resulted in the loss of livelihoods and the destruction of thousands of animals.

PBD Biotech developed its Actiphage biotechnology to provide the first blood test for accurate diagnosis of these diseases, and it was proven successful in helping to eradicate bovine TB from a Devon farm. Actiphage has since secured inclusion in the UK Government’s list of tests for exceptional private use on cattle herds in England.

This success has created interest in using the test in humans, as there is currently no blood test to help with early-stage TB screening.

Actiphage is being investigated by researchers from the University of Leicester in clinical trials with patients who have both latent and active TB infections. Early findings from the clinical trial are to be announced at the international conference of the American Thoracic Society in Dallas (21 May) with the full paper available later in 2019, subject to peer review.

Mark has held a number of senior leadership roles throughout his 20 years’ experience in public and private healthcare. His appointment is announced as PBD Biotech declares its first multi-million pound funding round to support the test’s regulatory validation and ongoing commercialisation.

Commenting on his new role, Mark said, “I am excited about what the future holds for PBD Biotech, and keen to build on our fast-growing reputation as a leader in mycobacterial diagnostics.

“Actiphage is unique as it is able to detect the presence of only live pathogen in samples, separating out any vaccine-antibodies, which offers it significant benefits as a disease diagnostic.”

Mark succeeds Dr Berwyn Clarke, who co-founded the company and, following his retirement as CEO, is to become a non-executive director on PBD Biotech’s Board.

Dr Clarke said, “The scale of the mycobacterial problem – animal, human and food – that Actiphage is addressing is enormous, which is why the test’s potential across these market sectors and geographies is huge.

“PBD Biotech has hit so many milestones in such a short time span – with European and American patents, international trials, proven scientific success and a Canadian subsidiary. Mark’s knowledge of pharma and healthcare will be invaluable as PBD Biotech continues to gain traction for its transformational tool in disease diagnosis and management.”

Share:

Related posts

Loading...
global unmet need for rapid molecular diagnostic for human TB

Targeting global unmet need for rapid molecular diagnostic for human TB

January 19, 2023
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis (TB) and will be suspending its commercial Johne’s Testing Service.
global unmet need for rapid molecular diagnostic for human TB

Targeting global unmet need for rapid molecular diagnostic for human TB

January 19, 2023
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis...
Marie Roskrow

TB blood-test developers PBD Biotech appoint Dr Marie Roskrow as Chair

January 17, 2023
Identifying those most at risk of active TB disease becomes a priority as fatalities increase. In response to this need, PBD Biotech is announcing that it has appointed Dr Marie Roskrow to chair its board and has expanded its scientific...
Marie Roskrow

TB blood-test developers PBD Biotech appoint Dr Marie Roskrow as Chair

January 17, 2023
Identifying those most at risk of active TB disease becomes a priority as fatalities increase. In response to this need,...
Pictured from left are Ray Harris from Foresight, Sandy Reid of Mercia Asset Management, Jane Theaker of PBD Biotech and Mark Wilcockson of British Business Bank

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

October 17, 2022
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic with potential to revolutionise management of TB.
Pictured from left are Ray Harris from Foresight, Sandy Reid of Mercia Asset Management, Jane Theaker of PBD Biotech and Mark Wilcockson of British Business Bank

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

October 17, 2022
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic...
Mondana Cook, Chief Operating Officer at PBD Biotech

Mondana Cook joins PBD Biotech to bring human TB diagnostic to market

July 19, 2022
New Chief Operating Officer brings experience of tuberculosis vaccine and precision medicine.
Mondana Cook, Chief Operating Officer at PBD Biotech

Mondana Cook joins PBD Biotech to bring human TB diagnostic to market

July 19, 2022
New Chief Operating Officer brings experience of tuberculosis vaccine and precision medicine.
1 2 … 6 Next »

developers of phage-based diagnostics

Contact Us

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!
PBD Biotech

More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB

Read More
PBD Biotech

Delighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies

Read More
PBD Biotech

Testing 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease

Read More